The new report shows that diabetes weight loss drugs can reduce the risk of Alzheimer’s.

Originally developed to treat GLP-1 receptor agents, such as Type 2 diabetes, especially Semaglutide (Sale to Ozempic and WEGOVY), the drugs are now raising interest in the potential to protect brain health. Two recent research and editorials Zama neurology I suggest that these drugs can help reduce the risk of dementia.

Dementia, including Alzheimer’s and related disorders, is one of the fastest growing public health problems. It affects nearly 7 million Americans today and is expected to double by 2060. The newly approved Alzheimer’s drugs such as Lecanemab and Aducanumab have attracted attention and remain concerns about effectiveness and safety. This is already widely used and interested in reconstructing existing drugs.

According to a multi-cohort study conducted by the University of Florida, GLP-1RAS and SGLT2 in inhibitors (SGLT2IS) have found that the risk of Alzheimer’s disease and related dementia (ADRD) is significantly lower than other diabetes drugs.

Data of more than 90,000 patients Researchers reported GLP-1RA users had a 33% lower risk, and SGLT2I users had a 43% reduction in ADRD than other glucose lowered drugs. The SGLT2 inhibitor showed slightly larger opponents, but the difference between the two classes was not statistically significant, and both suggest that both can provide similar protective effects.

no way Second study It supports the idea that the GLP-1 receptor agent, led by researchers at Galway University, can help reduce the risk of dementia. In a systematic review and meta-analysis of 26 randomly clinical trials, including more than 164,000 participants, researchers discovered statistically significant association between GLP-1 receptor agent and dementia risk.

Unlike Florida studies, Golway analysis has not found a similar advantage for SGLT2 inhibitors or Pioglitazone. This discovery suggests that GLP-1 receptor agents can play a more pronounced role in protecting cognitive function compared to other heart protection diabetes drugs.

GLP-1 receptor agents such as Semaglutide were originally developed to reduce weight loss of insulin, blood sugar, and to lose weight of patients with type 2 diabetes.

Researchers have found that GLP-1 receptors exist not only in the pancreas and gastrointestinal tracts, but also in the brain, heart and immune system. In animal studies, GLP -1RA has shown that it reduces brain inflammation, improves synaptic plasticity, and reduces the accumulation of amyloid -β and tau proteins, the main features of Alzheimer’s disease.

at editorial Post Zama neurologyDr. Diana Thiaa of the University of San Francisco describes these brain effects as “very promising” with new agents, especially with new agents, such as Semagluide.

She mentioned an ongoing test on a double and triple hormonal agent that can provide greater neurotrosis potential for the next few years, saying, “We are on the cliff.”

The major III phase clinical trials, including Evoke and Evoke Plus, are currently underway to evaluate the effect of Semaglutide in an individual with early Alzheimer’s illness. If these results are confirmed, the clinical approach to diabetes and dementia, especially how the two conditions can be approached from the aging population, which often coexists.

GLP-1 receptor agent is not risk. Common side effects include the loss of nausea, vomiting and dry muscle mass, especially for elderly people who are vulnerable to breeding. More rarely, the patient can experience pancreatitis, and preclinical studies have raised concerns about the risk of thyroid cancer, but have not yet been observed by humans.

© 2025 Science X Network